Gene Therapy for Multiple Sulfatase Deficiency Shows New Momentum
Early work with an ex vivo gene therapy approach is pointing to real gains: higher sulfatase activity and fewer symptoms tied to multiple sulfatase deficiency (MSD) in preclinical testing. At Children’s Hospital of Philadelphia (CHOP), researchers have been building a careful path toward therapy for MSD, a difficult condition that touches many organs and systems at once.
What MSD Is—and Why It’s So Challenging
Multiple sulfatase deficiency stems from changes in the SUMF1 gene. Those changes block the body’s ability to activate sulfatases—enzymes needed to break down specific storage materials inside cells. When these materials aren’t cleared, they build up. Over time, that buildup drives serious health problems, with neurological decline standing out as one of the most burdensome parts of the disease for many families.
Progress Through Collaboration
To move the science forward, the CHOP team is working alongside clinical partners, basic researchers, and advocacy organizations. Together, they’re mapping how MSD typically progresses across a wide range of severities. That shared dataset helps them pinpoint measurable signs—biomarkers—that could guide future clinical trials and make it possible to see, with confidence, whether a treatment is helping.
How the Gene Therapy Is Designed
Because MSD affects many systems, any potential treatment needs broad reach. CHOP investigators are studying different ways to deliver gene therapy, with a particularly promising strategy centered on hematopoietic stem cell transplantation. The idea is to use the body’s own blood-forming cells as couriers so therapy can reach multiple organs. As principal investigator Dr. Rebecca Ahrens-Nicklas explains, the team uses a lentiviral vector to insert a working copy of the gene linked to MSD into a patient’s own bone marrow cells. Those cells are modified outside the body and then—this is the key—returned so they can take root and do their work over time.
Signals of Benefit in Animal Studies
In a recent preclinical study using a mouse model, the treatment approach increased sulfatase activity and supported healthier cellular housekeeping. It also helped normalize glycosaminoglycan levels, a readout that reflects how well breakdown and clearance are happening. Beyond those lab measures, treated animals showed reduced neuroinflammation and better cognitive performance—signs that the therapy’s effects reached the brain, where MSD often hits hardest.
What Comes Next
This research is an important first step in showing that ex vivo gene therapy can address core features of MSD. The team is preparing the groundwork for clinical trials, with cautious optimism that more than one gene therapy candidate may be ready to move ahead. The aim is steady and clear: develop options that could make a tangible difference for individuals and families living with this condition.
Support That Makes the Work Possible
Funding for this study came from the Irish Health Research Board, the MSD Action Foundation, and the CHOP Research Institute. Additional backing from NIH grants supported the ongoing push to advance genetic therapies and translate lab findings into potential treatments.
About Children’s Hospital of Philadelphia
Founded in 1855, Children’s Hospital of Philadelphia is a nonprofit leader in pediatric care and research. CHOP couples hands-on patient care with training for the next generation of pediatric specialists. Its research programs fuel discoveries that benefit children well beyond Philadelphia, with care delivered on the main campus and across a broad network of affiliated sites throughout the region.
Frequently Asked Questions
What is multiple sulfatase deficiency (MSD)?
MSD is a rare genetic condition caused by changes in the SUMF1 gene. Those changes prevent activation of sulfatase enzymes, which are needed to clear specific storage materials inside cells. Without working sulfatases, those materials build up and drive disease.
What does “ex vivo” gene therapy mean in this context?
It means a patient’s own bone marrow cells are collected, modified outside the body with a lentiviral vector carrying a working copy of the affected gene, and then returned so they can help restore needed sulfatase activity.
What improvements were seen in the preclinical study?
In a mouse model, treatment increased sulfatase activity, supported healthier glycosaminoglycan levels, and improved cellular function. Researchers also observed reduced neuroinflammation and better cognitive outcomes in treated animals.
Why is collaboration important for MSD research?
MSD varies in severity and affects multiple systems. By working with clinicians, scientists, and advocacy groups, researchers can track the natural course of the disorder, define useful biomarkers, and design clinical trials that clearly measure benefit.
How is this work being funded?
Support comes from the Irish Health Research Board, the MSD Action Foundation, the CHOP Research Institute, and NIH grants dedicated to advancing genetic therapies.
